Sunshine Biopharma (SBFM) Operating Income (2011 - 2026)

Sunshine Biopharma has reported Operating Income for 15 years, with the latest figure at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 7.71% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$6.3 million (down 10.84% YoY), and the FY2025 full-year result was -$6.2 million, down 7.14% from the prior year.
• Operating Income for Q1 2026 stood at -$1.4 million, up from -$1.8 million in the prior quarter.
• The five-year high for Operating Income was -$695796.0 in Q2 2022, with the low at -$23.4 million in Q4 2022.
• Historically, Operating Income has averaged -$2.7 million across 5 years, with a median of -$1.3 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 8255.16% — and 2023, when it soared 94.92%.
• Sunshine Biopharma's Operating Income stood at -$23.4 million in 2022, then soared by 94.92% to -$1.2 million in 2023, then plunged by 71.64% to -$2.0 million in 2024, then grew by 12.16% to -$1.8 million in 2025, then rose by 22.03% to -$1.4 million in 2026.
• The last three Operating Income figures came in at -$1.4 million (Q1 2026), -$1.8 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.